11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism

Matthias K Auer, James M Hawley, Christian Lottspeich, Martin Bidlingmaier, Andrea Sappl, Hanna F Nowotny, Lea Tschaidse, Marcus Treitl, Martin Reincke, Brian G Keevil and Nicole Reisch

1Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany, 2Department of Clinical Biochemistry, Manchester University Foundation NHS Trust, Manchester Academic Health Sciences Centre, Southmoor Rd, Manchester, UK, 3Department for Radiology, Neuroradiology and Interventional Radiology, Trauma Centre Murnau, Germany, and 4Clinic and Polyclinic for Radiology, Clinical Centre of the University of Munich, LMU Munich, Germany

Abstract

Objective: Differentiation of an adrenal from an ovarian source of hyperandrogenemia can be challenging. Recent studies have highlighted the importance of 11-oxygenated C19 steroids to the androgen pool in humans. The aim of this study was to confirm the origin of 11-oxygenated androgens in females and to explore their potential use in the diagnostics of hyperandrogenic disorders.

Methods: We measured testosterone and its precursors (dehydroepiandrosterone-sulfate and androstenedione) and 11-oxygenated androgens (11β-hydroxyandrostenedione (11-OHA4) and 11-ketotestosterone (11-KT)) in the periphery, adrenal and ovarian veins in four different cases of hyperandrogenism in females (polycystic ovary syndrome (PCOS), primary bilateral macronodular adrenal hyperplasia, Sertoli–Leydig cell tumor and ovarian steroid cell tumor).

Results: Two patients demonstrate excessive testosterone secretion in neoplastic ovarian tumors which was not paralleled by a significant secretion of 11-oxygenated androgens as determined by adrenal and ovarian vein sampling. In androgen-secreting bilateral adrenal macronodular hyperplasia, steroid profiles were characterized by elevated 11-KT and 11-OHA4 concentrations in adrenal veins and the periphery. In the patient with PCOS, peripheral 11-KT concentrations were slightly elevated in comparison to the other patients, but the 11-KT and 11-OHA4 concentrations were comparable in ovarian veins and in the periphery.

Conclusion: This study confirms that 11-OHA4 and 11-KT are not biosynthesized by the ovary. We propose that the testosterone/11-KT ratio as well as 11-OHA4 could help identify predominant adrenal androgen excess and distinguish neoplastic and non-neoplastic ovarian androgen source.

Significance statement

This study confirms that 11β-hydroxyandrostenedione (11-OHA4) and 11-ketotestosterone (11-KT) are not biosynthesized by the human ovary. We propose that the testosterone/11-KT ratio as well as 11-OHA4 could help to identify predominant adrenal androgen excess and distinguish neoplastic and non-neoplastic ovarian androgen source.

Introduction

Disorders of androgen excess are common in the general female population affecting up to 15% of women (1). Most of these women suffer from polycystic ovary syndrome (PCOS) (2) or non-classic congenital adrenal hyperplasia
In case of suspected neoplastic androgen secretion, differentiation between an adrenal or ovarian origin can be challenging and require suppression testing (4, 5, 6, 7, 8, 9), extensive imaging diagnostics (10, 11) and invasive procedures such as selective venous sampling (4). Even though 11-oxygenated 19-carbon steroids have been known for decades, they have recently gained increasing attention because of their contribution to several hyperandrogenic disorders (12, 13, 14). The term collectively refers to the 11β-hydroxyandrostenedione (11-OHA4), 11β-hydroxytestosterone (11-OHT), 11-ketoandrostenedione (11-KA4) and 11-ketotestosterone (11-KT) steroids. Among these, it has been demonstrated that 11-KT and its derivate 11-KT-dihydrotestosterone act at the androgen receptor with equal potency to the classic androgens testosterone and dihydrotestosterone, respectively (15) highlighting their clinical significance (14). Androstenedione (A4) is converted to 11-OHA4 by cytochrome P450 11β-hydroxylase (CYP11B1), then to 11-KA4 through the action of 11β-hydroxysteroid dehydrogenase type 2 and finally to 11-KT by Aldo-keto reductase family 1 member C3 (AKR1C3) (16) (Fig. 1). In contrast to 11-OHA4 and 11-OHT, 11-KT and 11-KA4 are considered to be mainly produced in peripheral tissues (16). As the biosynthesis of 11-oxygenated androgens depends on cytochrome P450 family 11 subfamily B member 1 (CYP11B1), an adrenal-specific enzyme, they should also be adrenal-specific (13). It has been shown that 11-oxygenated androgens are elevated in adrenal-related androgen excess as CAH or premature adrenarche and Cushing’s disease (14, 17, 18). In addition, they may also be elevated in some (19, 20), but not all patients (21) with PCOS. However, as there is also in-vitro data claiming that there is a relevant production of 11-KT derived from the gonads (15), details of the biosynthesis of 11-oxygenated androgens in humans are debatable as direct evidence in terms of in-vivo data of localized secretion patterns is absent. If 11-oxygenated androgens are highly specific for adrenal androgen secretion, it would support their utility in the diagnostic workup of hyperandrogenism in women.

By presenting four cases of women with rare or challenging causes of androgen excess who had undergone an extensive diagnostic workup including peripheral as well as adrenal vein and ovarian vein blood sampling, our aim was to confirm the source of 11-oxygenated androgens production and to explore if their peripheral measurement could benefit the differential diagnostic workup of cases with an unclear source of androgen excess.

**Methods**

**Subjects**

All patients were seen at the outpatient clinic of the Medizinische Klinik IV, Klinikum der Universität München, LMU Munich. Written informed consent was obtained from the individuals described in this case series and all patients participated in our patient registries and
biobanks that were approved by the Ethical review board of the Ludwig Maximilian University, Munich (Bio AI/DSD, ethical approval no. 19-558, NeoExNET, ethical approval no. 152-10).

**Hormonal assays**

Adrenocorticotropic hormone (ACTH), luteinizing hormone, follicle-stimulating hormone, β-human chorionic gonadotropin, estradiol, cortisol and dehydroepiandrosterone sulfated metabolite (DHEAS) measurements were determined using the Liaison chemiluminescence immunoassays (DiaSorin, Sallugia, Italy). Total testosterone, 17-OHP, A4, 11-KT and 11-OHA4 were quantified by LC-MS/MS. Steroid extraction and quantitation were conducted as previously described (22). Serum 11-KT and 11-OHA4 were determined in preserved samples retrospectively. In the case of selective venous sampling, the presented results refer to the mean values of two to three successful samplings per site. For adrenal venous sampling, mean values of both sides are presented, as there was no significant lateralization in the presented cases.

**Results**

**Case descriptions**

Case 1 (macronodular adrenal hyperplasia) was a 45-year-old woman who had suffered from secondary amenorrhea since the age of 33. She was further suffering from poorly controlled diabetes, hirsutism, presented with cushingoid stigmata and was severely obese (BMI 43.9 kg/m²). Moderate hyperandrogenemia was diagnosed with a total serum testosterone of 2.9 nmol/L (0.31–2.29 nmol/L) (Fig. 2, Supplementary Table 1, see section on supplementary materials given at the end of this article). Cortisol suppression following 1 mg dexamethasone was insufficient (6.6 µg/dL) and suppressed ACTH levels indicated an adrenal source of glucocorticoid- and androgen-excess (Supplementary Table 1). A CT scan revealed bilateral (macronodular) adrenal hyperplasia (Fig. 3A), and a gynecological examination provided no evidence of an ovarian tumor. Due to the larger left nodule, the patient was referred for unilateral adrenalectomy.

Case 2 (Sertoli-Leydig cell tumor) was a 72-year-old woman presenting with significant hirsutism and male-pattern hair loss starting approximately 3 months before referral to our endocrine outpatient unit. She had a history of unilateral ovariectomy and hysterectomy due to endometriosis. Total serum testosterone concentration was extremely elevated at 19.7 nmol/L (0.31–2.29 nmol/L). 17-OHP was also elevated, while DHEAS and A4 were within their respective age- and sex-specific reference ranges. There was an adequate cortisol suppression following the intake of 1 mg dexamethasone while there was no significant suppression of testosterone or DHEAS (Supplementary Table 1). An abdominal CT scan revealed nodular hyperplasia of the right adrenal (1 cm), while there was no evidence of a tumor in the remaining left ovary. In a subsequent PET-CT scan, there was significant tracer accumulation in the left ovary (Fig. 3B). Simultaneous selective adrenal and ovarian venous sampling showed that testosterone concentrations from the adrenal veins were comparable to those sampled from the periphery while conversely, testosterone concentration from the remaining left ovarian vein was 31× greater than that obtained from the periphery (Fig. 2).

Case 3 (steroid-cell tumor) was a 54-year-old woman suffering from male-pattern hair loss and hirsutism that began 3 to 4 years ago. She had been postmenopausal for 2
No production of 11-oxygenated androgens in the human ovary

M K Auer and others

11-Oxygenated androgens

In all cases, 11-OHA4 levels in the adrenal veins were significantly higher than in the ovarian veins (Fig. 2). Conversely ovarian concentrations were either comparable to (Cases 2 and 4) or even lower than those obtained from the periphery (Case 3). Concentrations of 11-KT were not higher in the ovarian veins compared to the periphery in any of the cases with ovarian androgen excess. In Case 3, 11-KT derived from the healthy right ovary was not higher than in the periphery (0.5 vs 0.7 nmol/L; Supplementary Fig. 1). Systemic concentrations of 11-KT in the two patients with ovarian androgen excess were low in comparison to the patient with adrenal androgen excess due to bilateral macronodular adrenal hyperplasia (Fig. 3; Supplementary Fig. 1). In PCOS, there was no significant difference in 11-KT levels obtained from the different sampling sites (ovarian veins: 1.2 nmol/L; adrenal veins: 1.0 nmol/L, periphery: 1.2nmol/L). The 11-KT levels were about 2x times higher in the periphery compared to the 2 patients with neoplastic hyperandrogenism (Case 2: 0.6 nmol/L, Case 3: 0.7 nmol/L) (Fig. 2).

Discussion

To the best of our knowledge, this is the first study reporting in-vivo data from ovarian vein samplings for 11-KT and 11-OHA4 concentrations.

In all the study cases, adrenal and ovarian venous sampling confirmed that 11-OHA4 is secreted abundantly from the adrenal glands (12). In contrast, concentrations of 11-KT were not higher in the ovarian veins compared to the periphery in any of the patients with ovarian androgen excess. This finding confutes the results of a previous study that claims that 11-KT represents a major androgen produced in the human gonads in-vivo (15). Although it has been shown that 11β-hydroxysteroid dehydrogenase types 1 and 2 are expressed in testicular
Leydig and ovarian theca cells (15), our findings contradict the idea that gonadal 11-KT production significantly contributes to the systemic pool in females because *CYP11B1* is usually only expressed in negligible amounts in the gonads (23). An exception to this are patients with CAH in which aberrant adrenal tissue can be found within the testicles or ovaries (24, 25). The idea that 11-KT is produced in peripheral tissue from 11-OHA4 produced in the adrenal is supported by the observation that 11-KT levels did not differ between the sampling sites, considering the significantly higher 11-OHA4 levels in the adren al vein samples, especially. Peripheral 11-KT concentrations were also considerably higher in the patient with macronodular hyperplasia in comparison to the other patients. As selective venous sampling had not been performed in this patient due to the unequivocal imaging, we can only speculate on its major source, but it is likely to have been derived from the peripheral conversion of excessive amounts of 11-OHA4. As this patient was severely obese due to concomitant cortisol excess, it is conceivable that increased 11-KT secretion was derived from excessive adipose tissue conversion of 11-OHA4 and 11-KA4 by AKR1C3 that can be further stimulated by hyperinsulinemia (26).

In the patient with PCOS, peripheral 11-KT levels were only slightly higher than those in the two patients with tumorous ovarian androgen secretion. There was no difference in 11-KT levels obtained from the different sampling sites, again challenging the idea of a primarily ovarian 11-KT biosynthesis. While all published studies on PCOS and 11-oxygenated androgens (19, 20, 27) showed elevated levels of 11-OHA4 in comparison to controls, 11-KT seems only to be elevated in some (19, 20), but not all women with PCOS (19, 27). An elevation of 11-KT seems to be primarily found in women with PCOS who are obese but not in those who are only over- or normal-weighted (19, 20). This may be due to AKR1C3 activity in adipose tissue (26). These discrepancies may also be explained by the fact that PCOS encompasses a wide variety of disease patterns (2), among other factors being defined by the degree of ovarian and adrenal androgen secretion (28, 29).

**Limitations**

A limitation of our study is the presentation of single cases that do not allow for the generalization of the results. Additionally, we did not measure 11-KA4 and 11-OHT levels. 11-OHT might have been a better marker to determine if ovarian tumors were able to directly 11β-hydroxylate testosterone to 11-OHT, especially as testosterone was more abundant than androstenedione in the ovarian vein samples. However, the quantification of these steroids is hampered by the fact that there are no deuterated internal standards currently available. Finally, we did not perform selective venous sampling in the patients with macronodular hyperplasia, given the obvious adrenal origin of androgen excess.

Nonetheless, although our cases are anecdotal, we find them encouraging regarding the potential utility of peripheral 11-oxygenated androgen measurements for improving the differential diagnosis in severe hirsutism and/or hyperandrogenemia. Our data support the assumption that 11-KT concentrations are low relative to the high concentrations of circulating testosterone which are typical of androgen-secreting ovarian tumors. The data are particularly encouraging as two different entities of these ovarian tumors were examined in our study, providing similar results. A testosterone/11-KT ratio may therefore be a promising variable to differentiate neoplastic ovarian from non-neoplastic ovarian sources such as PCOS, while 11-OHA4 may further help to differentiate between adrenal and ovarian tumors.

**Conclusion**

Our data clearly illustrate and give direct evidence that 11-oxygenated androgens are of adrenal origin and not produced in the human ovary as claimed previously (15). Based on our findings, we hypothesize that a serum testosterone/11-KT ratio has the potential for differentiating neoplastic from non-neoplastic ovarian androgen excess. Furthermore, measurement of serum 11-OHA4 may help delineate ovarian from adrenal androgen secretion. Larger studies are required to further investigate the diagnostic performance of 11-KT and 11-OHA4 in larger cohorts of rare cases of hyperandrogenism.

---

**Supplementary materials**

This is linked to the online version of the paper at [https://doi.org/10.1530/EJE-220518](https://doi.org/10.1530/EJE-220518).

---

**Declaration of interests**

The authors report no conflicts of interest in this work. Nicole Reisch is on the editorial board of the *European Journal of Endocrinology*. Nicole Reisch was not involved in the review or editorial process for this paper, on which he/she is listed as an author.
Funding
This work was supported by the IFCAH grant 2013 to NR and by the Deutsche Forschungsgemeinschaft (Heisenberg Professorship 325768017 to NR and Projektnummer: 314061271-TRR205 to NR).

References
1 Sanchón R, Gambineri A, Alpañes M, Martínez-García MÁ, Pasquali R & Escobar-Morreale HE. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Human Reproduction 2012 27 1209–1216. (https://doi.org/10.1093/humrep/des028)
2 Rosenberg RL & Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews 2016 37 467–520. (https://doi.org/10.1210/er.2015-1104)
3 Carmina E, Rosato F, Janni A, Rizzo M & Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2006 91 2–6. (https://doi.org/10.1210/jc.2005-1045)
4 Kaltsaas GA, Isidori AM, Kola BP, Skelly RH, Chew SL, Jenkins PJ, Monson JP, Grossman AB & Besser GM. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. Journal of Clinical Endocrinology and Metabolism 2003 88 2634–2643. (https://doi.org/10.1210/jc.2002-029022)
5 László FA, Tóth S, Kocsis J, Pávó I & Szécsi M. Testosterone-secreting gonadotropin-responsive adenoma cell line and its treatment with the antiandrogen flutamide. Journal of Endocrinological Investigation 2001 24 622–627. (https://doi.org/10.1007/BF03343904)
6 Pascale MM, Pugnet M, Roberts M, Rousett H, Déchaud H, Dutrไกลx-Berger N & Tournier A. J. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clinical Endocrinology 1994 41 S71–S76. (https://doi.org/10.1111/j.1365-2265.1994.tb07820.x)
7 Picón MJ, Lan J, Saras JS, Recaener JD, Cluet R, Gonzalez MA & Rovira A. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour. European Journal of Endocrinology 2000 142 619. (https://doi.org/10.1530/ej.0.1420619)
8 Rao CV. Human adrenal LH/hCG receptors and what they could mean for adrenal physiology and pathology. Molecular and Cellular Endocrinology 2010 329 33–36. (https://doi.org/10.1016/j.mce.2010.05.012)
9 Derksen J, Nagesser SK, Meinders AE, Haak HR & van de Velde C. J. Identification of viralizing adenomas in hirsute women. New England Journal of Medicine 1994 331 968–973. (https://doi.org/10.1056/NEJM199410333131502)
10 Lee G, Lee JH & Lee WA. F-18 FDG PET/CT imaging of a Leydig cell tumor. Clinical Nuclear Medicine 2010 35 202–204. (https://doi.org/10.1097/RLU.0b013e3181cc6467)
11 Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugnet MM & Rosenberg RL. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society® clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2018 103 1233–1257. (https://doi.org/10.1210/jc.2018-00241)
12 Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MK, Layman LC, Honma S, Sasano H & Rainey WE. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. Journal of Clinical Endocrinology and Metabolism 2013 98 1182–1188. (https://doi.org/10.1210/jc.2012-2912)
13 Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP, Rainey WE & Auchus RJ. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. European Journal of Endocrinology 2016 174 601–609. (https://doi.org/10.1530/EJE-15-1881)
14 Nowotny HF, Braun L, Vogel F, Billingmaier M, Reincke M, Tschaide SJ, Auer MK, Lottspeich C, Wudy SA, Hartmann MF et al. oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing’s disease. European Journal of Endocrinology 2022 187 663–673. (https://doi.org/10.1530/EJE-22-0320)
15 Imamichi Y, Yuhki KI, Orisaka M, Kitano T, Mukai K, Ushikubi F, Taniguchi T, Umezawa A, Miyamoto K & Yazawa T. 11-Ketotestosterone is a major androgen produced in human gonads. Journal of Clinical Endocrinology and Metabolism 2016 101 3582–3591. (https://doi.org/10.1210/jc.2016-2318)
16 Turcu AF & Rege J. Aucrust RJ & Rainey WE. 11-Oxygenated androgens in health and disease. Nature Reviews Endocrinology 2020 1–13.
17 Rege J, Turcu AF, Kasa-Vubu JZ, Lerario AM, Aucrust RJ, Smith JM, White PC & Rainey WE. 11-Ketotestosterone is the dominant circulating bioactive androgen during normal and premature adenarche. Journal of Clinical Endocrinology and Metabolism 2018 103 4589–4598. (https://doi.org/10.1210/jc.2018-00736)
18 Wise-Oringer BK, Burghard AG, O’Day P, Hassoun A, Sopher AB, Fennovy I, Williams KM, Yuguin PM, Nanakumar R, McMahon DJ et al. The unique role of 11-oxygenated C19 steroids in both premature adenarche and premature pubarche. Hormone Research in Paediatrics 2020 93 460–469. (https://doi.org/10.1159/000513236)
19 Yoshida T, Matsuura T, Miyado M, Saito K, Iwasa T, Matsuura Y, Ogata T, Irahara M & Fukamil M. 11-Oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocrine Journal 2018 65 979–990. (https://doi.org/10.1507/endocrj. EJ18-0212)
20 O’Reilly MW, Kempegowda P, Jenkins C, Taylor AE, Quanson JL, Starbeck KH & Ait W. 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2017 102 840–848. (https://doi.org/10.1210/jc.2016-3265)
21 Taylor AE, Ware M, Breslow E, Pyle L, Severn C, Nadeau KJ, Chan CL, Kelsey MM & Cree-Green M. 11-Oxygenated androgens in adolescents With polycystic ovary syndrome. Journal of the Endocrine Society 2020 4 3203. (https://doi.org/10.1210/jendso/bavo307)
22 Hawley JM, Adaway JE, Owen LJ & Keevil BG. Development of a total serum testosterone, androstenedione, 17-hydroxyprogesterone, 11β-hydroxysteroidenedione and 11-ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical sample stability. Chemicals and Laboratory Medicine (CLLM) 2020 58 741–752. (https://doi.org/10.1515/cllm-2019-0959)
23 Rege J, Nakamura Y, Wang T, Merchen TD, Sasano H & Rainey WE. Transcriptomics profile reveals differentially expressed transcripts between the human adrenal zona fasciculata and zona reticularis. Journal of Clinical Endocrinology and Metabolism 2014 99 E518–E527. (https://doi.org/10.1210/jc.2013-3198)
24 Kolli V, da Cunha IW, Kim S, Iben JR, Mallappa A, Li T, Gaynor A, Coon SL, Quezado MM & Merke DP. Morphologic and molecular characterization of adrenals and adrenal rest affected by congenital adrenal hyperplasia. Frontiers in Endocrinology (Lausanne) 2021 12 730947. (https://doi.org/10.3389/fendo.2021.730947)
25 Schroder MAM, Turcu AF, O’Day P, van Herwaarden AE, span PN, Aucrust RJ, Sweep FCJ & Claassens-van der Grinten HL. Production of 11-oxygenated androgens by testicular adrenal rest tumors. Journal of Clinical Endocrinology and Metabolism 2022 107 e272–e280. (https://doi.org/10.1210/cenin/dgab598)
26 Paulukinas RD, Mesaro CA & Penning TM. Conversion of classical and 11-oxygenated androgens by insulin-induced AKR1C3 in a model of
of human PCOS adipocytes. *Endocrinology* 2022 163 bqac068. (https://doi.org/10.1210/endocr/bqac068)

27 Taylor AE, Ware MA, Breslow E, Pyle L, Severn C, Nadeau KJ, Chan CL, Kelsey MM & Cree Green M. 11-Oxyandrogens in adolescents With polycystic ovary syndrome. *Journal of the Endocrine Society* 2022 6 bvac037. (https://doi.org/10.1210/jendso/bvac037)

28 Yildiz BO & Azziz R. The adrenal and polycystic ovary syndrome. *Reviews in Endocrine and Metabolic Disorders* 2007 8 331–342. (https://doi.org/10.1007/s11154-007-9054-0)

29 Maas KH, Chuan S, Harrison E, Cook-Andersen H, Duleba AJ & Chang RJ. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome. *Fertility and Sterility* 2016 106 1252–1257. (https://doi.org/10.1016/j.fertnstert.2016.06.039)

Received 15 June 2022
Revised version received 30 September 2022
Accepted 13 October 2022